Kaempferol attenuates angiotensin II-induced myocardial fibrosis in association with macrophage glycolytic and PKM2/HIF-1α signaling changes
Year: 2026
Type: article
Abstract: Introduction Myocardial fibrosis develops through sustained interactions among activated fibroblasts, infiltrating immune cells, and metabolic signals within the injured myocardium. This study evaluated whether kaempferol attenuated angiotensin II (Ang II)-induced myocardial fibrosis in association with changes in macrophage pyruvate kinase M2 (PKM2)/hypoxia-inducible factor 1α (HIF-1α)-linked glycolytic and inflammatory activation. Methods The primary in vivo cohort comprised 48 male C57BL/6J mice randomized to four groups (12 per group) and treated for 28 days. Separate exploratory cohorts comprised 48 mice assigned to a dose-response/positive-comparator study and 42 mice assigned to single-dose plasma and myocardial exposure profiling. Donor-matched bone marrow-derived macrophages from six additional mice were studied under eight conditions incorporating kaempferol, PKM2 overexpression, Pkm2 knockdown, and matched controls. Results In the primary cohort, kaempferol reduced interstitial collagen volume fraction from 16.07% ± 2.10% to 9.14% ± 2.26% and increased left ventricular ejection fraction from 48.01% ± 2.97% to 56.87% ± 2.56%. In the separate dose-response cohort, collagen volume fraction declined from 16.00% ± 2.10% with Ang II + vehicle to 13.70% ± 1.90%, 11.20% ± 1.80%, and 9.20% ± 2.00% with kaempferol at 2.5, 5, and 10 mg/kg/day, respectively; the losartan comparator group had a value of 8.60% ± 1.70%. Plasma kaempferol concentration was highest at the 0.5-h sampling point and myocardial concentration at 1 h after a single 10 mg/kg intraperitoneal dose. In macrophages, kaempferol reduced glycolytic and inflammatory readouts and weakened conditioned-medium-induced fibroblast activation. Fibroblast protein measurements showed partial restoration of α-smooth muscle actin (α-SMA) and collagen I abundance with PKM2 overexpression and lower abundance after Pkm2 knockdown. Discussion These findings support an antifibrotic action associated with reduced inflammatory macrophage enrichment and suppression of PKM2/HIF-1α-linked glycolytic activation, while not establishing PKM2 as a direct kaempferol target or the pathway as the sole mediator of cardioprotection. Because kaempferol may exhibit assay-dependent interference or nonspecific biological effects, the in vitro findings and putative pathway involvement require cautious interpretation; the available data do not demonstrate direct PKM2 engagement or clinical efficacy.
Source: Frontiers in Pharmacology
Authors: Ming Zhang(Conceptualization, Formal analysis, Investigation, Methodology, Supervision, Writing – original draft, Writing – review & editing), Zhengbo Zhu(Formal analysis, Investigation, Methodology, Writing – original draft), Qian Zhou(Data curation, Investigation, Writing – original draft), Fei Qi(Investigation, Methodology, Writing – original draft), Hanli Li(Investigation, Validation, Writing – original draft)
Institutions: Anhui Institute of Medicine, Hefei University of Technology
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236145763
